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ORIGINAL ARTICLE 
CLINICO-PATHOLOGICAL PROFILE AND OUTCOMES OF PATIENTS 
WITH POLYCYTHAEMIA VERA, ESSENTIAL THROMBOCYTHAEMIA 
AND IDIOPATHIC MYELOFIBROSIS: A TERTIARY CARE CENTER 
EXPERIENCE FROM SOUTHERN PAKISTAN 
Muhammad Shariq Shaikh, Mohammad Usman Shaikh, Salman Naseem Adil, 
Mohammad Khurshid*, Zeeshan Ansar Ahmed 
Department of Pathology and Laboratory Medicine, *Department of Oncology, The Aga Khan University Hospital, Karachi-Pakistan 
Background: The “Philadelphia Negative Classic Myeloproliferative Neoplasms” include 
polycythaemia vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF). 
These three disorders share several clinical and laboratory features including JAK2 V617F 
mutation. Our objectives were to determine the clinico-pathological profile and outcomes of 
Pakistani patients with polycythaemia vera (PV), essential thrombocythaemia (ET) and idiopathic 
myelofibrosis (IMF) in order to have an insight regarding behaviour of these conditions. 
Methods: A retrospective analysis of all the cases of PV, ET and IMF diagnosed at our institute 
from January 1995 to December 2013 was performed. Age, gender, clinical presentation, 
laboratory investigations, treatment provided and duration of follow-up were included for analysis. 
Appropriate statistics were utilized for calculation of data. Results: A total of 58 patients were 
diagnosed as PV, ET or IMF during the study period. Male to female ratio was 1.1:1. Forty five 
percent (n=27) patients came to medical attention due to abnormal laboratory results, 3 had 
cerebrovascular events, 3 had pruritus, and 1 patient each with gangrene and Budd-Chiari 
syndrome. Haemorrhage was not seen in any patient. Sixty percent (n=35) patients were treated 
with phlebotomy, hydroxyurea and aspirin alone or in combination. None of the patients 
transformed to myelofibrosis (MF) or myelodysplasia (MDS) during the mean (±SD) follow-up 
period of 57.2±50 months. One patient with ET transformed to acute myeloid leukaemia 9 years 
after the diagnosis. Conclusions: This study demonstrated a relatively more benign form of PV, 
ET and IMF with lesser frequency of symptoms, good response to treatment and less likelihood of 
transformation to MF, MDS or AML. 
Keywords: Myeloproliferative neoplasms, Polycythaemia vera, Essential thrombocythaemia, 
Idiopathic myelofibrosis, Pakistan  
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INTRODUCTION  
The Myeloproliferative Neoplasms (MPNs) are 
clonal disorders of haematopoietic stem cells 
characterized by overproduction of one or more 
myeloid cell lineages. Conditions which are 
considered myeloproliferative neoplasms under the 
classification used by the World Health 
Organization1 include chronic myelogenous 
leukaemia (CML), polycythaemia vera (PV), 
essential thrombocythaemia (ET), idiopathic 
myelofibrosis (IMF), chronic neutrophilic 
leukaemia (CNL), chronic eosinophilic leukaemia-
not otherwise specified (CEL-NOS), mastocytosis, 
and myeloproliferative neoplasms unclassifiable 
(MPN-U). Located in Philadelphia chromosome 
(Ph), BCR-ABL1 gene is found positive only in 
CML.  
The three classic Ph-negative MPNs (PV, 
ET and IMF) share several clinico-pathological 
features. All three are characterized by marrow 
hyper cellularity, risk of thrombosis, haemorrhage 
and leukemic transformation. JAK2 V617F 
mutation is another feature which is shared by 
these three conditions. It is found positive in 
approximately 95%, 60% and 50% cases of PV, ET 
and IMF respectively. JAK2 V617F mutation is 
often said to be associated with more aggressive 
nature of these conditions. In PV and ET, it has 
been found associated with higher haemoglobin2,3 
and granulocyte levels,4,5 a greater incidence of 
pruritus,2 a higher rate of fibrotic transformation2 
and thrombosis6. Lower platelet counts and 
increased risk of transformation to PV in JAK2 
positive ET7,8 and more aggressive disease 
phenotype with shortened overall survival have 
been described with JAK2 positive IMF.  
Patients with PV and ET come to medical 
attention either due to abnormal laboratory results 
or may have symptoms related to 
myeloproliferation like pruritus, thrombosis, 
headaches, erythromelalgia, visual disturbances 
and haemorrhage. Most patients with IMF on the 
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contrary present with debilitating fatigue, anaemia, 
early satiety secondary to marked splenomegaly 
and constitutional symptoms.9 
Transformation into acute myeloid 
leukaemia (AML), myelodysplastic syndrome 
(MDS) and myelofibrosis (MF) are major causes 
of death in PV.10 Median survival in PV if treated 
is 10 years. Most patients with ET enjoy a normal 
life expectancy without associated disease-related 
complications11 as evolution into either AML or 
MF is unusual.12 Median survival in IMF 
according to the series used for constructing the 
International Prognostic Scoring System (IPSS) 
was reported to be 69 months.13 
The goal of treatment in PV and ET is to 
relieve symptoms and prevent thrombosis without 
increasing the risk of bleeding.14 Several 
therapeutic modalities based on risk stratification 
of these conditions have been described.14 The 
role of phlebotomy, low-dose aspirin, 
hydroxyurea, interferon-alpha15 and anagrelide is 
well documented.  
Literature search revealed lack of studies 
from Pakistan addressing these three conditions. 
Therefore, we aimed in determining clinico-
pathological profile and outcomes of patients 
with PV, ET and IMF diagnosed at our centre. 
This study will provide an insight to the 
clinicians dealing with these three Philadelphia-
negative classic myeloproliferative neoplasms. 
MATERIAL AND METHODS 
This was a retrospective analysis performed in the 
Section of Hematology, The Aga Khan University 
Hospital. An exemption (2967-Pat-ERC-14) was 
granted by institutional ethical review board for 
conducting this study. All patients diagnosed as 
PV, ET or IMF from January 1995 to December 
2013 were included in the analysis. Medical 
records were retrieved with the help of 
institutional data management system. 
The diagnosis of all three disorders was 
made in accordance with the WHO criteria in use 
at the time of first presentation (WHO criteria 
2001 and 2008).  Before that, diagnosis was made 
based on Polycythaemia Vera Study Group 
Criteria (PVSG). 
Age, gender, clinical presentation, 
laboratory investigations, treatment provided and 
duration of follow-up were included for analysis. 
Statistical package for social sciences (SPSS-19) 
was utilized for data analysis (SPSS Inc., 
Chicago, IL, USA). Frequency and percentage 
were calculated for categorical variables and 
mean and standard deviation were computed for 
quantitative variables.  
RESULTS 
A total of 58 patients were diagnosed as PV, ET or IMF 
during the study period. Male to female ratio was 1.1:1 
with mean±SD age of 57.3±13.3 for males and 
56.3±16.6 for females. The mean age and gender 
distribution of study population with respect to the 
diagnosis is shown in table-1. 
For PV and ET, the most common reason for 
consultation was abnormal complete blood count (CBC) 
findings carried out as routine testing. Three of 6 
patients with IMF presented with constitutional 
symptoms. Two patients (1 male, 1 female) with PV and 
one female with ET presented with stroke. None of the 
patients with PV or ET had erythromelalgia or 
haemorrhage. Other key presenting features and JAK2 
V617F mutation status are detailed in table-1. 
Haematological parameters of study population are 
shown in table-2. 
 Thirty seven out of 58 patients (64%) 
continued their follow-up in haematology outpatient 
department. Of those who were treated, combination of 
phlebotomy, hydroxyurea and aspirin was the most 
common strategy for PV patients (Table 3). Twelve 
patients who required therapeutic phlebotomies, 
mean±SD haematocrit were 54.9±6.7 at the time of 
diagnosis. The mean±SD units of whole blood (450ml 
each approximately) taken out were 5.0±6.0 over the 
mean±SD follow-up period of 77.8±59.5 months. 
Interferon alpha and anagrelide were not utilized in any 
patient. Most of the patients with ET received 
hydroxyurea and aspirin in combination. None of the 
patients with PV and ET transformed into MF or MDS 
with a mean±SD follow-up period of 71.3±57.2 and 
52±47 months respectively. Evolution into AML was 
seen in one female patient with ET. She developed 
AML 9 years after the initial diagnosis and subsequently 
succumbed to this aggressive condition. All four 
patients with IMF were treated differently (Table 3) 
with only one patient requiring red cell transfusions. 
Three patients with IMF (1 on no treatment, 1 on 
hydroxyurea and 1 on aspirin only) remained stable with 
a median follow-up of 32±18.7 months. Treatment 
details and follow-up duration of study population are 
shown in table-3. 
JAK2 V617F mutation was found positive in 
89.3%, 58.3% and 66.7% of patients with PV, ET and 
IMF respectively (Table-1). Of 31 symptomatic 
patients, 25 (81%) were positive for this mutation 
including patients with cerebrovascular events, gangrene 
and Budd-Chiari syndrome (Table 4). Similarly, 
haematological parameters were higher in patients with 
JAK2 V617F positive mutation status except for the 
platelet count which was low (Table-4). Single patient 
with ET who transformed to AML was negative for this 
mutation. 
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Table-1: Age, gender, clinical features and JAK2 V617F mutation status of study population 
 PV ET IMF 
Number of Patients (%) 28 (48.3%) 24 (41.4%) 6 (10.3%) 
Males 19 (67.8%) 5 (20.8%) 6 (100%) 
Females 9 (32.2%) 19 (79.2%) 0 
Age in years (Mean±SD)    
Males 52.5±12.6 61.4±8.3 59.5±19.8 
Females 64±14.8 53.6±15.9 - 
Presenting symptoms    
Constitutional symptoms (night sweats, weight loss, fever) 3 (10.7%) 0 3 (50%) 
Abnormal laboratory findings 14 (50%) 13 (54.2%) - 
Symptoms influencing daily activities (fatigue, insomnia, inactivity) 4 (14.3%) 4 (16.6%) 1 (16.7%) 
Complaints related to myeloproliferation (Bone pains, itching) 3 (10.7%) 5 (20.8%) 1 (16.7%) 
 Cerebrovascular event 2 (7.1%) 1(4.2%) - 
 Gangrene 1 (3.6%) - - 
 Budd-Chiari 1 (3.6%) - - 
 Symptoms of splenomegaly 0 1(4.2%) 1 (16.7%) 
Palpable Splenomegaly 8 (28.6%) - 4 (66.7%) 
JAK2 V617F Mutation(a)    
     Positive 25 (89.3%) 14 (58.3%) 4 (66.7%) 
     Negative 3 (10.7%) 10 (41.7%) 2 (33.3%) 
(a) JAK-2 mutation analysis in 9 patients was performed during follow-up period when this test became available in 2008; all were positive 
Table-2: Haematological parameters of study population 
Haemoglobin Haematocrit RBC MCV MCH WBC Platelets 
Diagnosis 
Sex 
(g/dl) (%) (X 1012/L) (fl) (pg) (X 109/L) (X 109/L) 
Male (n=19) 18.2±2.0 56.4±6.2 8.8±6.1 75.1±17.0 24.9±3.7 20.4±13 470±182 
PV 
Female (n=9) 17.1±2.2 54.3±6.7  6.8±0.9 81.1±13.1 26.0±4.4 22±13.8  569±228 
Male (n=5) 11.6±1.9 37.7±6.1 4.0±0.1 83.6±3.4 27.5±1.6 16.1±10.4 1375±781 
ET 
Female (n=19) 13±1.4 39.8±4.5 4.9±0.7 84.8±8.5 27.8±3.1 11.5±3.7 968±442 
IMF Male (n=6) 11.4±2 34.6±7.0 3.7±0.4 74.1±14.3 24.5±5.9 20.3±17 636±623 
Table-3: Treatment details and follow-up of patients who continued their treatment in our institution (n=37) 
Treatment PV ET IMF 
    Wait and Watch 0 0 1 (25%) 
    Hydroxyurea 0 5 (26.3%) 1 (25%) 
    Aspirin 0 2 (10.5%) 1 (25%) 
    Phlebotomy + Hydroxyurea + Aspirin 12 (85.7%) 0 0 
    Hydroxyurea + Aspirin 2 (14.3%) 12 (63.2%) 0 
    Hydroxyurea + RBC transfusions 0 0 1 (25%) 
In follow-up 14 (50%) 19 (79%) 4 (66.6%) 
Lost to follow 14 (50%) 5 (21%) 2 (33.3%) 
Mean follow-up (months) 71.3±57.2 52±47 32.0±18.7 
 
Table-4: Clinical features and haematological 
parameters in patients with respect to JAK2- 
(V617F) mutation status 
 JAK2 V617F  
Positive 
JAK2 V617F  
Negative 
Number of patients 43 (74%) 15 (26%) 
Abnormal laboratory results 18 (41.8%) 9 (60%) 
Constitutional symptoms 5 (11.6%) 1 (6.7%) 
Symptoms of splenomegaly 1 (2.3%) 1 (6.7%) 
Symptoms influencing daily 
activities 
7 (16.3%) 2 (13.3%) 
Symptoms related to 
myeloproliferation 
8 (18.7%) 1 (6.7%) 
Cerebrovascular events 2 (4.7%) 1 (6.7%) 
Budd-Chiari Syndrome 1 (2.3%) 0 
Gangrene 1 (2.3%) 0 
Haemoglobin (g/dl) 15.5±3.2 13.3±3.0  
Haematocrit (%) 48.4±10.5 41.5±8.8 
Red Blood Cells (X 1012/L ) 7.3±4.7 4.8±0.6 
White blood cells (X 109/L) 19.4±12.3 10.1±2.9 
Platelets (X 109/L) 716±485  876±535 
DISCUSSION 
Our study ascertained several important facts in 
Pakistani patients with PV, ET and IMF. To the best 
of our knowledge, it is the first study from Pakistan 
detailing clinico-pathological profile of patients with 
PV, ET and IMF. The median age at presentation for 
all three conditions in our study is comparable to that 
described in the literature (Table-1).  Sex ratios for 
PV, ET and IMF in this study are quite different from 
international data. Male to Female ratio in PV was 
2.1:1 which is almost double. Female preponderance 
in ET (female to male ratio of 2:1) has been reported 
in several studies however, female to male ratio was 
found to be 3.8:1 in this study. All 6 patients with 
IMF were males. Although PV and ET are identified 
by chance in a proportion of patients, almost half of 
the patients with these conditions in our study came 
to medical attention due to incidental abnormal 
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laboratory findings (Table-2). Only three (10.7%) 
patients with PV had pruritus whereas, it has been 
reported in as high as 68% of the patients with PV.16 
Thrombotic events were present in four (14.3%) 
patients with PV (cerebrovascular event in 2, Budd-
Chiari syndrome in 1 and gangrene in 1). These 
figures are comparable to international data.17 In ET 
however, only one (4.2%) patient presented with 
cerebrovascular thrombosis. Incidence rates of 
thrombosis in ET varying from 9 to 22 percent have 
been described in various studies.12,18 
Patients who continued their follow-up in 
our institute, hydroxyurea in combination with 
aspirin was the most common treatment modality 
utilized for PV and ET. Considering the follow-up 
period of 77.8±59.5 months in patients with PV who 
required phlebotomies, the requirement for it was low 
(5.0±6.0 units of whole blood). Patient with both PV 
and ET responded well to hydroxyurea with no 
events of thrombosis, transformation or death (except 
one patient). Higher risk of both disease 
transformation and death in hydroxyurea resistance 
disease has been published in literature.19,20 In 
patients with MF, calculation of scores according to 
Dynamic International Prognostic Scoring System21 
(DIPSS) revealed following results: intermediate 
risk-1 (5 patients) and intermediate risk-2 (1 patient). 
One patient with intermediate risk-2 DIPSS score 
remained clinico-haematologically stable during the 
follow-up period of 20 months. Median survival in 
intermediate risk-2 category according to DIPSS is 4 
years.21  
The prevalence of JAK2 V617F mutation in 
this study is comparable to available international 
literature (Table-1). The more aggressive clinico-
pathological features in JAK2 V617F mutation 
positive patients as well as lower platelet counts are 
in accordance with other reported studies.7,8 
Interestingly, the single patient with ET who 
developed AML after 9 years of initial diagnosis was 
negative for this mutation. 
Besides being the first study from Pakistan 
detailing clinico-pathological features and outcomes 
of patients with PV, ET and IMF, other strength of 
this study is its long duration (19 years; from 1995–
2013) and reasonable follow-up (57.2±50 months). 
Although the sample size is not large enough 
however, considering the annual incidence of 0.5-2.5 
cases per 100,000 populations in western countries, 
the current data from a tertiary care centre provides a 
passable insight into behaviour of these conditions in 
study population. We could not provide the data on 
frequency of other mutations like exon 12 mutation 
in PV and MPL gene in ET due to unavailability of 
these tests at our institute. Similarly, quantification of 
JAK2 V617F burden to assess risk of thrombosis 
could not be scrutinized. 
CONCLUSIONS 
This study demonstrated a relatively more benign 
form of PV, ET and IMF with lesser frequency of 
symptoms and good response to treatment. 
Transformation to aggressive forms like 
myelofibrosis and myelodysplasia were also not seen 
in any patient. The possible influence of genetic and 
environmental factors on milder phenotype of these 
conditions in Pakistani population needs further 
exploration. 
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